Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

The present disclosure provides an azulene ring-containing compound, its use, and an organic photoelectric device including the same. The azulene ring-containing compound is a compound comprising a structure of Formula I. The organic photoelectric device includes an anode, a cathode, and one or more organic thin film layers located between the anode and the cathode; and at least one of the organic thin film layers contains the above-mentioned azulene ring-containing compound comprising the structure of Formula I. The azulene ring-containing compound provided by the present disclosure has an energy level difference Est0.3 eV between the lowest singlet state S.sub.1 and the lowest triplet state T.sub.1, and has a light-emitting mechanism of a thermally activated delayed fluorescent material, and can be used as a thermally activated delayed fluorescent material for organic photoelectric device, so that the light-emitting efficiency of the device is improved.

The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2 (HIF-2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Provided are a compound for an organic electronic element that can improve the luminous efficiency, stability and life span of the element, an organic electronic element comprising the same, and an electronic device thereof.

A series of benzosuberene analogues demonstrate effective inhibition of tubulin polymerization, cytotoxicity against human cancer cell lines, and vascular disruption in tumors.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having excellent luminous properties can be produced.

Methods for preparing a variety of ladderane precursors, ladderane compounds and ladderane lipids are provided. Also provided are methods of preparing a liposome from the ladderane lipids disclosed herein, and compositions thereof. Aspects of the invention include encapsulated one or more cargo moieties in the liposome or compositions thereof and use of the subject liposome compositions as vehicles in drug delivery, imaging, diagnostics and other medical applications. Aspects of the methods disclosed herein include administering a liposomal composition comprising a pharmaceutical agent to a subject under conditions sufficient to deliver the composition to a site of interest in the subject, and release the pharmaceutical agent from the liposomal composition.

To provide an organic electroluminescent device in which energy efficiency is improved. An organic electroluminescent device includes a pair of electrode layers formed of an anode layer and a cathode layer, and a luminescent layer arranged between the pair of electrode layers, in which the luminescent layer includes a host material and a dopant material, and the dopant material is an anthracene-based compound represented by formula (1), and the luminescent layer further includes a polycyclic aromatic compound represented by formula (2) or a multimer of a polycyclic aromatic compound having a plurality of structures represented by formula (2).

##STR00001##

Provided is a compound of Chemical Formula 1:

##STR00001##

where R.sub.1 and R.sub.2 are each independently hydrogen, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, tri(C.sub.1-60 alkyl)silyl, a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing at least one of O, N, Si and S,

R.sub.3 and R.sub.4 are each independently hydrogen, deuterium, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, tri(C.sub.1-60 alkyl)silyl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing at least one of O, N, Si and S, and

Ar is C.sub.6-60 aryl, or C.sub.2-60 heteroaryl containing at least one of O, N, Si and S, wherein the C.sub.6-60 aryl, or C.sub.2-60 heteroaryl is substituted with 1 to 5 substituents each selected from the group consisting of a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, and tri(C.sub.1-60 alkyl)silyl,

and an organic light emitting device including the same.